InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia

NCT05961059 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2024-11-07

No results posted yet for this study

Summary

The goal of this clinical trial is to test a new Shigella vaccine (InvaplexAR-DETOX) in combination with a new adjuvant (dmLT) in healthy participants. The main questions it aims to answer are:

* Is the new Shigella vaccine (with and without the new adjuvant) safe and well tolerated?
* How wel does the new Shigella vaccine stimulate the immune system in combination with the new adjuvant, and without the new adjuvant?

Participants will receive three vaccinations at 28-day intervals. Researchers will compare the results of participants vaccinated with the vaccine in combination with the adjuvant to the results of participants vaccinated with the vaccine only and to the results of participants vaccinated with a placebo (fake vaccine).

Conditions

  • Shigellosis
  • Bacillary Dysentery

Interventions

BIOLOGICAL

2.5 μg InvaplexAR-Detox

2.5 μg intramuscular dose of Sfl2a InvaplexAR-Detox.

BIOLOGICAL

10 μg InvaplexAR-Detox

10 μg intramuscular dose of Sfl2a InvaplexAR-Detox.

BIOLOGICAL

0.1 μg of dmLT

0.1 μg intramuscular dose of double mutant (LT R192G/L211A) enterotoxigenic Escherichia coli heat labile toxin (dmLT).

BIOLOGICAL

Placebo

Placebo vaccination with commercially available saline solution.

Sponsors & Collaborators

  • Centre for Infectious Disease Research in Zambia

    collaborator OTHER
  • PATH

    collaborator OTHER
  • Walter Reed Army Institute of Research (WRAIR)

    collaborator FED
  • Göteborg University

    collaborator OTHER
  • European Vaccine Initiative

    collaborator OTHER
  • European and Developing Countries Clinical Trials Partnership (EDCTP)

    collaborator OTHER_GOV
  • Leiden University Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-10
Primary Completion
2025-05-31
Completion
2025-05-31
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05961059 on ClinicalTrials.gov